Breast Cancer Trial, Not Yet Recruiting NCT07543250 Sponsor: xuliang Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT07543250
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with breast cancer that is hormone receptor-positive (HR+) and HER2-negative, and whose cancer has either come back or spread to other parts of the body, confirmed by a tissue or cell sample test.
  • People whose cancer has a specific gene change called a PIK3CA mutation, confirmed by a laboratory test on a tissue or blood sample.
  • People for whom complete medical records, scan results, lab results, and follow-up information are available and traceable from the start of treatment.
  • People who have already started a treatment regimen including a drug called Inavolisib combined with hormone-based therapy, with or without another type of drug called a CDK4/6 inhibitor, as part of their regular medical care — and for whom full details of that treatment are on record.
  • People who have given their consent to take part in this observational study, where this is required by the ethics committee at the treating centre.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are currently taking part in another clinical trial that involves an active treatment or intervention at the time of enrolment.
  • People who have another active cancer at the same time that requires its own systemic treatment, or for whom key medical data needed to assess outcomes is missing.
  • People who have a condition — such as a mental health condition, social circumstances, or geographic location — that the trial investigator considers would make regular follow-up difficult or unlikely.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 13691534938

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
xuliang
Registry
ClinicalTrials.gov
Start date
16 May 2026
Est. completion
31 December 2026

Primary endpoints

Real-World Progression-Free Survival (rwPFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov